How much funding has Addex Therapeutics raised?

Addex Therapeutics has raised $155.9M in total funding, most recently a Extension Round.

Who are Addex Therapeutics's investors?

Addex Therapeutics's investors include Index Ventures, SR One.

When was Addex Therapeutics founded?

Addex Therapeutics was founded in 2002.

Where is Addex Therapeutics headquartered?

Addex Therapeutics is headquartered in Plan-les-Ouates, Switzerland.

What industry is Addex Therapeutics in?

Addex Therapeutics operates in Biopharmaceutical, Biotech, Drug Discovery, Healthcare, Therapeutics.

How many employees does Addex Therapeutics have?

Addex Therapeutics has 11-50 employees.

Addex Therapeutics

IPO

Allosteric modulators for human health

Public · Plan-les-Ouates, Switzerland · Founded 2002 · $155.9M raised

Headquarters: Plan-les-Ouates
Employees: 11–50
Founded: 2002
Business Model: B2B
Website: addextherapeutics.com

Total Funding: $155.9M
Last Round: $900K Extension RoundAug 2022
Rounds: 7
Type: Public

About

Addex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Plan-les-Ouates, Geneva, Switzerland, focused on the discovery and development of novel orally available small molecule allosteric modulators for neurological disorders. The company's pipeline includes programs targeting mGlu5, mGlu2, mGlu7, and GABAB receptors for indications including post-stroke recovery, traumatic brain injury, substance use disorder, chronic cough, and anxiety-related disorders. Addex also launched a spin-out, Neurosterix, to advance M4 PAM allosteric modulators for schizophrenia. The company trades on SIX Swiss Exchange and has US ADRs listed.

Summary

Addex Therapeutics is a Biopharmaceutical company based in Plan-les-Ouates, Switzerland, founded in 2002. It has raised $155.9M in total across 7 rounds, most recently a $900K Extension Round round in Aug 2022. Investors include Index Ventures and SR One.

LinkedIn X (Twitter)